December 11, 2017, Ahmedabad. Novo Nordisk India and Torrent Pharmaceuticals took their partnership to the next level with the inauguration of the extended insulin manufacturing facility at the latter’s Indrad factory today.

The facility was inaugurated by His Excellency Peter Taksøe-Jensen, Ambassador to India, Embassy of Denmark, Jinesh Shah, Executive Director, Torrent Pharmaceuticals, Frederik Kier, Senior Vice President, Region AAMEO, Novo Nordisk, and Melvin D’souza, Managing Director, Novo Nordisk India.

“With the expansion of the facility at Indrad, we reiterate our commitment to ensuring the provision of affordable, quality insulin for people with diabetes. At Novo Nordisk, we are committed to addressing the growing diabetes burden by working with likeminded stakeholders to change diabetes,” said Frederik Kier, Senior Vice President, Region AAMEO, Novo Nordisk.

Melvin D’souza, Managing Director, Novo Nordisk India, said: “The growth of diabetes in India is alarming and people with diabetes have a right to access affordable, quality medication. Through this partnership, we will continue to ensure the provision of cost-effective yet high-quality medication.”

Torrent Pharmaceuticals and Novo Nordisk are marking 25 years of partnership in India. The journey started in 1992 with the manufacture and launch of insulin in 40 IU vials. In 2009, an integrated manufacturing and vial packaging plant was inaugurated.

Jinesh Shah, Executive Director, Torrent Pharmaceuticals said: “As we embark on a new growth path at Torrent, we look forward to working more collaboratively with Novo Nordisk to ensure the diabetes challenge in India is addressed effectively.”

Congratulating Torrent and Novo Nordisk, His Excellency Peter Taksøe-Jensen, Ambassador to India, Embassy of Denmark said: “It’s a proud moment for Indo-Danish collaboration as Torrent and Novo Nordisk mark 25 years of partnership. Denmark is committed to supporting the Indian Government’s Make in India initiative and this new expanded facility is a reflection of the support.”

The enhanced production facility will be equipped to address the growing diabetes challenges: India is home to 72.9 million people with diabetes (according to the International Diabetes Federation 8th Atlas). The number is expected to go up to 134.3 million by 2045. As world leaders in diabetes care, Novo Nordisk partners with patients, policymakers, healthcare professionals and non-governmental organisations to address diabetes risk factors, thus ensuring that people with diabetes are diagnosed earlier. Through the Changing Diabetes® Barometer project, Novo Nordisk has partnered with seven state governments to create awareness about diabetes. As part of the project, till date, 700,000 people have been educated about diabetes and over 3700 doctors and paramedics have been trained through various capacity building programs.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

About Torrent Pharmaceuticals Ltd.

Torrent Pharma, with annual revenues of more than INR 5,800 crores is the flagship Company of the INR 18,300 crore Torrent Group. Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking amongst the top 50 brands (AIOCD AWACS Dataset) in India. Its widespread international presence also include several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries. Torrent has a fully equipped Research Centre, employing almost 900 scientists, to support the Company’s operation and product pipeline for both Domestic and Overseas markets. The Company’s manufacturing plants located at Indrad, Baddi, Sikkim, Dahej, Pithampur and Vizag have facilities to produce Formulation and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.